Patients with rare diseases are increasingly working to find and fund their own cures. But should they have to?

Minovia Therapeutics said Monday that the Food and Drug Administration granted fast-track and rare-pediatric-disease designations to its lead investigational compound. The drug, MNV-201, is in Phase 2 ...